Geode Capital Management
TERN

Geode Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Geode Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122M Buy
2,316,544
+219,902
+10% +$9.03M 0.01% 967
2025
Q4 		$84.7M Buy
2,096,642
+382,090
+22% +$8.83M 0.01% 1189
2025
Q3 		$12.9M Buy
1,714,552
+81,203
+5% +$518K ﹤0.01% 2262
2025
Q2 		$6.09M Buy
1,633,349
+59,145
+4% +$185K ﹤0.01% 2633
2025
Q1 		$4.35M Buy
1,574,204
+57,726
+4% +$236K ﹤0.01% 2726
2024
Q4 		$8.4M Buy
1,516,478
+308,999
+26% +$2.09M ﹤0.01% 2473
2024
Q3 		$10.1M Buy
1,207,479
+85,617
+8% +$704K ﹤0.01% 2373
2024
Q2 		$7.64M Buy
1,121,862
+255,941
+30% +$1.55M ﹤0.01% 2488
2024
Q1 		$5.68M Buy
865,921
+25,462
+3% +$166K ﹤0.01% 2631
2023
Q4 		$5.46M Buy
840,459
+52,344
+7% +$277K ﹤0.01% 2658
2023
Q3 		$3.96M Buy
788,115
+604
+0.1% +$3.83K ﹤0.01% 2760
2023
Q2 		$6.89M Buy
787,511
+482,795
+158% +$5.63M ﹤0.01% 2521
2023
Q1 		$3.61M Buy
304,716
+127,068
+72% +$1.21M ﹤0.01% 2777
2022
Q4 		$1.81M Buy
177,648
+8,800
+5% +$58.6K ﹤0.01% 3089
2022
Q3 		$994K Buy
168,848
+89,524
+113% +$333K ﹤0.01% 3389
2022
Q2 		$196K Sell
79,324
-99,987
-56% -$200K ﹤0.01% 4284
2022
Q1 		$532K Sell
179,311
-1,624
-0.9% -$6.93K ﹤0.01% 3901
2021
Q4 		$1.28M Sell
180,935
-12,401
-6% -$103K ﹤0.01% 3587
2021
Q3 		$2.01M Buy
193,336
+50,267
+35% +$521K ﹤0.01% 3348
2021
Q2 		$1.75M Buy
143,069
+12,806
+10% +$218K ﹤0.01% 3325
2021
Q1 		$2.87M Buy
+130,263
New +$2.86M ﹤0.01% 3084

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Geode Capital Management's TERN Position: Q1 2026 in Review

Geode Capital Management increased its Terns Pharmaceuticals (TERN) stake by 10% in Q1 2026, buying an estimated $9.03M and bringing the position to 2,316,544 shares worth $122M. The position accounts for 0.01% of the portfolio, ranked #967.

Geode Capital Management first reported a position in TERN in Q1 2021 and has held it in 21 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Geode Capital Management held 2,316,544 shares of Terns Pharmaceuticals worth $122M as of Q1 2026.
  • Geode Capital Management bought 219,902 Terns Pharmaceuticals shares in Q1 2026, an estimated $9.03M.
  • Terns Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #967 holding.
  • Geode Capital Management first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.